• The prevalence of obesity in the United States is projected to be over 50% by 2030. Glucagon-like peptide 1 (GLP-1) agonist therapies are important for people seeking to achieve and maintain reductions in weight and reduce cardiovascular and other health risks; however, they are widely associated with GI side effects that prevent people from reaching their goals.

• The majority of people prescribed GLP-1s discontinue therapy during the first year.
  • 45% to 65% of patients cite GI side effects as the reason for discontinuing therapy.

• There is a significant unmet need and large market opportunity for a therapy that can reduce these GI adverse events that keep people from reaching their weight loss and other important health goals.

• Gastroparesis is a chronic, severe and debilitating disorder that may be associated with dysfunction in the enteric nervous system, causing the movement of food from the stomach to the small intestine to slow or stop, and preventing or disrupting normal digestion.

• Gastroparesis is characterized by symptoms of nausea, vomiting, abdominal pain, early satiety and post-prandial fullness and is associated with a delay in stomach emptying. For most patients, the prevailing chronic symptom they experience is persistent nausea that intensifies after eating.

Learn about our clinical trial